Carter Elenz
CIK 1518385 · View on SEC EDGAR ↗
First SEC filing: July 8, 2013 · Latest: July 8, 2013
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 7, 2013 | UZF | J | 10,075 | — | — | 10,075 Direct | — | Acquired | (price as of 2026-08-19) |
| June 7, 2013 | UZF | J | 7,385 | — | — | 7,385 Direct | — | Acquired | (price as of 2026-08-19) |
| June 7, 2013 | UZF | J | 4,677 | — | — | 4,677 Direct | — | Acquired | (price as of 2026-08-19) |
| June 7, 2013 | UZF | J | 37,250 | — | — | 37,250 Direct | — | Acquired | (price as of 2026-08-19) |
| June 7, 2013 | UZF | J | 24,833 | — | — | 24,833 Direct | — | Acquired | (price as of 2026-08-19) |
| June 7, 2013 | UZF | J | 24,075 | — | — | 24,075 Direct | — | Acquired | (price as of 2026-08-19) |
| April 1, 2013 | UZF | A | 8,642 | — | — | 8,642 Direct | — | Acquired | (price as of 2026-08-19) |
| April 1, 2013 | UZF | A | 31,950 | — | — | 31,950 Direct | — | Acquired | (price as of 2026-08-19) |
| April 2, 2012 | UZF | A | 6,335 | — | — | 6,335 Direct | — | Acquired | (price as of 2026-08-19) |
| April 2, 2012 | UZF | A | 21,300 | — | — | 21,300 Direct | — | Acquired | (price as of 2026-08-19) |
| April 15, 2011 | UZF | A | 4,012 | — | — | 4,012 Direct | — | Acquired | (price as of 2026-08-19) |
| April 15, 2011 | UZF | A | 20,650 | — | — | 20,650 Direct | — | Acquired | (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 7, 2013 | UZF | Restricted Stock Units [F1] | Common Stock | $0.00 | April 1, 2016 | 10,075 | Acquired |
| June 7, 2013 | UZF | Restricted Stock Units [F1] | Common Stock | $0.00 | April 2, 2015 | 7,385 | Acquired |
| June 7, 2013 | UZF | Restricted Stock Units [F1] | Common Stock | $0.00 | April 15, 2014 | 4,677 | Acquired |
| June 7, 2013 | UZF | NQ Stock Option (Right to Buy) [F1] | Common Stock | — | April 1, 2023 | 37,250 | Acquired |
| June 7, 2013 | UZF | NQ Stock Option (Right to Buy) [F1] | Common Stock | — | April 2, 2022 | 24,833 | Acquired |
| June 7, 2013 | UZF | NQ Stock Option (Right to Buy) [F1] | Common Stock | — | April 15, 2021 | 24,075 | Acquired |
| April 1, 2013 | UZF | Restricted Stock Units | Common Stock (8,642) | $0.00 | April 1, 2016 | 8,642 | Acquired |
| April 1, 2013 | UZF | Option (Right to Buy) | Common Stock (31,950) | $36.34 | April 1, 2023 | 31,950 | Acquired |
| April 2, 2012 | UZF | Restricted Stock Units | Common Stock (6,335) | $0.00 | April 2, 2015 | 6,335 | Acquired |
| April 2, 2012 | UZF | Option (Right to Buy) | Common Stock (21,300) | $40.74 | April 2, 2022 | 21,300 | Acquired |
| April 15, 2011 | UZF | Restricted Stock Units | Common Stock (4,012) | $0.00 | April 15, 2014 | 4,012 | Acquired |
| April 15, 2011 | UZF | Option (Right to Buy) | Common Stock (20,650) | $48.97 | April 15, 2021 | 20,650 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2013 | $455,359 | — | $314,038 | $396,122 | — | — | $43,920 | $1,209,439 |
| 2012 | $435,417 | $133,119 | $258,088 | $313,651 | $115,211 | — | $62,344 | $1,317,830 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.